神经代谢轴:在心力衰竭中是一种新的治疗点
Praloy Chakraborty1, Sunny S Po1, Benjamin J Scherlag1
1Cardiovascular Section, Department of Internal Medicine, Heart Rhythm Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Life sciences
|September 29, 2023
概括
减少喷射分数 (HFrEF) 的心力衰竭涉及心脏代谢异常和自主神经系统失衡. 这篇评论探讨了神经代谢轴和神经调节.
科学领域:
- 心脏病学 心脏病学
- 代谢科学 代谢科学
- 神经科学是一个神经科学.
背景情况:
- 心脏代谢重塑之前心力衰竭减少喷射率 (HFrEF),导致心室功能障碍.
- 失调的心脏自主音调,标志着交感过度和降低的副交感活动,是心力衰竭 (HF) 的关键特征.
- 越来越多的证据表明,自主神经系统 (ANS) 活动与心脏代谢之间存在联系.
研究的目的:
- 在HFrEF的背景下研究"神经代谢轴".
- 确定神经调节策略是否可以缓解HFrEF中不良代谢重塑.
- 评估ANS活动在调节心脏新陈代谢中的作用,在HF进展期间.
主要方法:
- 在HFrEF中检查心脏新陈代谢和自主度之间的关系的研究文献综述.
- 慢性交感和副交感激活对心脏代谢通路的影响分析.
- 评估神经调节作为HFrEF的潜在治疗方法.
主要成果:
- 慢性交感激活 (β-上腺) 加剧了不适应的心脏代谢重塑.
- 胆固醇激活可以通过有利地调节关键调节分子来减轻代谢异常.
- 神经调节策略旨在恢复交感血管平衡,为HF提供潜在的非药物治疗方法.
结论:
- 神经代谢轴在HFrEF的病理生理学中发挥着关键作用.
- 通过神经调节调节ANS,通过向代谢功能障碍来治疗HFrEF是一个有希望的途径.
- 恢复交感血管平衡可能会逆转或减轻HFrEF中看到的不良心脏重塑.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
454
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
454
01:26Heart Failure Drugs: Inotropic Agents
611
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
611
01:29Heart Failure II: Pathophysiology
14
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
14
01:30Heart Failure V: Medical Management
12
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
12
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:22Heart Failure Drugs: β-Blockers
357
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
357